AI Article Synopsis
- LY354740 is a powerful mGlu2/3 agonist, but has limited absorption when taken orally; its prodrug, LY544344, enhances its bioavailability by being well-absorbed through the intestinal peptide transporter PEPT1.
- The study examined how LY544344 is absorbed in the intestines using a rat model, finding that it had significantly better absorption compared to LY354740.
- The absorption of LY544344 follows a Michaelis-Menten kinetic model, indicating that there is a maximum absorption rate and that increasing concentrations can lead to decreased efficiency due to saturation, particularly when competing with other substances like Gly-Sar.
Article Abstract
LY354740 is a potent mGlu2/3 agonist with a limited oral bioavailability. Its alanyl prodrug, LY544344, showed high affinity to the intestinal peptide transporter PEPT1, and improved the oral bioavailability of LY354740 in various animal models. The aim of the present study was to investigate the mechanism of in vivo absorption of the dipeptidic prodrug LY544344. The permeabilities of LY544344 and LY354740 were examined in the rat in situ single-pass intestinal perfusion model. The intestinal absorptive flux of LY354740 was shown to be very low in comparison with LY544344. The absorptive flux of LY544344 could best be described by a Michaelis-Menten process in parallel with a linear process. The estimated parameters were: J(max) = 26.7 x 10(-5) micromol/(cm(2)-s), K(m) = 2.6 mM. The absorptive permeability of LY544344 was reduced to approximately 5% of control in the presence of excess Gly-Sar, a known PEPT1 substrate. Intracellular accumulation of LY354740 and LY544344, estimated postperfusion, showed high levels of LY354740 over LY544344 at all perfusate concentrations studied. However, there was a decline in the intracellular ratio of LY354740 to LY544344 at higher concentrations, suggesting that the metabolic activation to release LY354740 is saturable.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/jps.21917 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
mGlu2/3 receptor agonist (LY354740) in anxiety.
Pharmacol Biochem Behav
September 2024
128 Mill Creek Road, Ardmore, PA 19003, United States. Electronic address:
mGlu2/3 Receptors (LY354740) in Anxiety mGlu2/3 receptors when activated decrease glutamate excitation on limbic synapses involved in anxiety. The orally active agonist compound LY354740 (or prodrug LY544344) was active in animal and human models of stress/anxiety. Later clinical studies showed efficacy in generalized anxiety in patients, validating this mechanism clinically.
View Article and Find Full Text PDFMetabotropic glutamate2/3 receptor agonism facilitates autonomic recovery after pharmacological panic challenge in healthy humans.
Int Clin Psychopharmacol
May 2016
Departments of aPsychiatry and Psychotherapy bPsychosomatic Medicine and Psychotherapy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany Departments of cFunctional Genomics dMolecular and Cellular Neurobiology, Center for Neurogenomics and Cognitive Research, Neuroscience Campus Amsterdam, VU University Amsterdam, Amsterdam, The Netherlands.
Group II metabotropic glutamate receptors (mGluR2/3) are suggested to modulate anxiety, arousal, and stress including autonomic control. However, no study has investigated mGluR2/3-related effects on baseline autonomic activity and reactivity to emotional challenge in humans as yet. Using a double-blind, randomized placebo-controlled, cross-over study design, we investigated the influence of a 1-week treatment with the mGluR2/3 agonist LY544344, prodrug of LY354740, on autonomic reactivity to a cholecystokinin tetrapeptide (CCK-4) panic challenge in eight healthy young men.
View Article and Find Full Text PDFThe intestinal absorption of a prodrug of the mGlu2/3 receptor agonist LY354740 is mediated by PEPT1: in situ rat intestinal perfusion studies.
J Pharm Sci
March 2010
Department of Pharmaceutics, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota 55455, USA.
Article Synopsis
- LY354740 is a powerful mGlu2/3 agonist, but has limited absorption when taken orally; its prodrug, LY544344, enhances its bioavailability by being well-absorbed through the intestinal peptide transporter PEPT1.
- The study examined how LY544344 is absorbed in the intestines using a rat model, finding that it had significantly better absorption compared to LY354740.
- The absorption of LY544344 follows a Michaelis-Menten kinetic model, indicating that there is a maximum absorption rate and that increasing concentrations can lead to decreased efficiency due to saturation, particularly when competing with other substances like Gly-Sar.
Transepithelial transport of the group II metabotropic glutamate 2/3 receptor agonist (1S,2S,5R,6S)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylate (LY354740) and its prodrug (1S,2S,5R,6S)-2-[(2'S)-(2'-amino)propionyl]aminobicyclo[3.1.0]hexane-2,6-dicarboxylate (LY544344).
Drug Metab Dispos
January 2009
Department of Pharmaceutics, College of Pharmacy, University of Minnesota, 308 Harvard St. SE, Weaver-Densford Hall 9-149, Minneapolis, Minnesota 55455, USA.
The limited oral bioavailability of the potent and selective group II metabotropic glutamate (mGlu) 2/3 receptor agonist, (1S,2S,5R,6S)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylate (LY354740), was shown to be improved by its peptidyl prodrug, (1S,2S,5R,6S)-2-[(2'S)-(2'-amino)propionyl]aminobicyclo[3.
View Article and Find Full Text PDFEfficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder.
Neuropsychopharmacology
June 2008
Orexigen Therapeutics, San Diego, CA 92130, USA.
LY354740, a potent and selective mGlu (metabotropic glutamate receptor)2/3 agonist, has shown efficacy in the treatment of generalized anxiety disorder (GAD). LY544344 is a LY354740 prodrug that increases LY354740 bioavailability. This 8-week study was designed to evaluate the efficacy, safety, and tolerability of LY544344 in the treatment of GAD.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!